Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | PAM | P19021 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9729336 | 0.98 | KMT2A (0.42) | KMT2AMEN1ALDH1A1L3MBTL1MAPK1 | |
| Hydrochloric Acid SCHEMBL506846 | 0.98 | KMT2A (0.42) | KMT2AMEN1ALDH1A1L3MBTL1MAPK1 | |
| Hydrochloric Acid SCHEMBL6869492 | 0.96 | KMT2A (0.41) | KMT2AMEN1ALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL16060676 | 0.82 | SOAT1 (0.45) | KMT2AMEN1ALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL12390375 | 0.82 | ESR1 (0.46) | KMT2AALDH1A1TP53LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL13835179 | 0.82 | IDO1 (0.44) | KMT2AMEN1ALDH1A1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL13836304 | 0.82 | MEN1 (0.46) | KMT2AMEN1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL24574882 | 0.80 | KMT2A (0.45) | KMT2AMEN1L3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL2033677 | 0.80 | L3MBTL1 (0.50) | KMT2AALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL11534926 | 0.80 | MAPT (0.48) | KMT2AMEN1ALDH1A1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922401-B | 4-hydroxy-3- (heteroaryl) pyridin-2-one APJ agonists for the treatment of cardiovascular disorders | 百时美施贵宝公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20190263791-A1 | 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263791-A1 | 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-29 | — | — | US | disclosed |
| EP-3530660-A1 | 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | Bristol-Myers Squibb Company (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-3530660-A1 | 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | Bristol-Myers Squibb Company (US) | 2019-08-28 | — | — | EP | disclosed |
| US-10336739-B2 | 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336739-B2 | 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3303330-B1 | 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3303330-B1 | 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20180273518-A1 | 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-27 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20060111381-A1 | Amidine compounds | MONASH UNIVERSITY (AU) | 2006-05-25 | — | — | US | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1558617-A1 | AMIDINE COMPOUNDS | Monash University (AU) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004033458-A1 | AMIDINE COMPOUNDS | MONASH UNIVERSITY (AU) | 2004-04-22 | — | — | WO | disclosed |
| EP-1140920-A1 | PIPERIDINES AS CCR5 MODULATORS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039125-A1 | PIPERIDINES AS CCR5 MODULATORS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| WO-1994026715-A1 | AMIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-24 | — | — | WO | disclosed |
| US-4152349-A | IMPROVED REACTIVITY, STORAGE STABILITY | THE UPJOHN COMPANY (US) | 1979-05-01 | — | — | US | disclosed |
| US-4152348-A | INHIBITION OF COLOR FORMATION ON STORAGE | THE UPJOHN COMPANY (US) | 1979-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336739-B2 | 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists | TBXA2R, ADRA2C, ADRA2A | KMT2A 2712/4885MEN1 4462/4885ALDH1A1 914/4885 |
| US-20180273518-A1 | 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS | TBXA2R, ADRA2C, ADRA2A | KMT2A 2712/4885MEN1 4462/4885ALDH1A1 914/4885 |
| US-20060111381-A1 | Amidine compounds | OPRM1, OPRD1, OPRK1 | KMT2A 2882/4885MEN1 3839/4885ALDH1A1 2428/4885 |
| US-20190263791-A1 | 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS | TBXA2R, ADRA2C, ADRA2A | KMT2A 2712/4885MEN1 4462/4885ALDH1A1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.